Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first
A new medicine for a kidney disease showed it works well when given every three months. The company plans to test it in more patients starting in 2027.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.